Prebiotics and synbiotics in ulcerative colitis

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.e42.
   PubMed Web of Science ®Google Scholar
• Kanai T, Matsuoka K, Naganuma M, et al. Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods. Korean J Intern Med. 2014;29:409–415.
   PubMed Web of Science ®Google Scholar
• Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol. 2013;48:315–321.
   PubMed Web of Science ®Google Scholar
• Ohkusa T, Koido S. Intestinal microbiota and ulcerative colitis. J Infect Chemother. 2015;21:761–768.
   PubMed Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–1283.
   PubMed Web of Science ®Google Scholar
• De Leon LM, Watson JB, Kelly CR. Transient flare of ulcerative colitis after fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2013;11:1036–1038.
   PubMed Web of Science ®Google Scholar
• Hill C, Guarner F, Reid G, et al. The international scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11:506–514.
   PubMed Web of Science ®Google Scholar
• Bindels LB, Delzenne NM, Cani PD, et al. Towards a more comprehensive concept for prebiotics. Nat Rev Gastroenterol Hepatol. 2015;12:303–310.
   PubMed Web of Science ®Google Scholar
• Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011;474:307–317.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Avni-Biron I, Ben-Bassat O. Probiotics and prebiotics in Crohn’s disease therapies. Best Pract Res Clin Gastroenterol. 2016;30:81–88.
   PubMed Web of Science ®Google Scholar
• SBU. Utvärdering av metoder i hälso- och sjukvården: en handbok. 1st ed. Stockholm: Statens beredning för medicinsk utvärdering (SBU); 2013.
   Google Scholar
• CONSORT. CONSORT 2010 [Internet]. c2010. [cited 2015 Aug 2]. Available from: http://www.consort-statement.org/consort-2010
   Google Scholar
• Roberfroid MB, Van Loo JAE, Gibson GR. The bifidogenic nature of chicory inulin and its hydrolysis products. J Nutr. 1998;128:11–19.
   PubMed Web of Science ®Google Scholar
• Van den Abbeele P, Gérard P, Rabot S, et al. Arabinoxylans and inulin differentially modulate the mucosal and luminal gut microbiota and mucin-degradation in humanized rats. Environ Microbiol. 2011;13:2667–2680.
   PubMed Web of Science ®Google Scholar
• Sato T, Matsumoto K, Okumura T, et al. Isolation of lactate-utilizing butyrate-producing bacteria from human feces and in vivo administration of Anaerostipes caccae strain L2 and galacto-oligosaccharides in rat model. FEMS Microbiol Ecol. 2008;66:528–536.
   PubMed Web of Science ®Google Scholar
• Winkler J, Butler R, Symonds E. Fructo-oligosaccharide reduces inflammation in a dextran sodium sulphate mouse model of colitis. Dig Dis Sci. 2007;52:52–58.
   PubMed Web of Science ®Google Scholar
• Lara-Villoslada F, De Haro O, Camuesco D, et al. Short-chain fructooligosaccharides, in spite of being fermented in the upper part of the large intestine, have anti-inflammatory activity in the TNBS model of colitis. Eur J Nutr. 2006;45:418–425.
   PubMed Web of Science ®Google Scholar
• Hoentjen F, Welling GW, Harmsen HJM, et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis. 2005;11:977–985.
   PubMed Web of Science ®Google Scholar
• Johansson MEV, Gustafsson JK, Sjöberg KE, et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One. 2010;5:e12238.
   PubMed Web of Science ®Google Scholar
• Casellas F, Borruel N, Torrejón A, et al. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment Pharmacol Ther. 2007;25:1061–1067.
   PubMed Web of Science ®Google Scholar
• Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut. 2005;54:242–249.
   PubMed Web of Science ®Google Scholar
• Siedner DL, Lashner BA, Brzezinski A, et al. An oral supplement enriched with fish oil, soluble fiber and antioxidants for corticosteroid sparing in ulcerative colitis: a randomised, controlled trial. Clin Gastroenterol Hepatol. 2005;3:358–369.
   PubMed Web of Science ®Google Scholar
• Bamba T, Kanauchi O, Andoh A, et al. A new prebiotic from germinated barley for nutraceutical treatment of ulcerative colitis. J Gastroenterol Hepatol. 2002;17:818–824.
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Fujiyama Y, Mitsuyama K, et al. Increased growth of Bifidobacterium and Eubacterium by germinated barley foodstuff, accompanied by enhanced butyrate production in healthy volunteers. Int J Mol Med. 1999;3:175–179.
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Serizawa I, Araki Y, et al. Germinated barley foodstuff, a prebiotic product, ameliorates inflammation of colitis through modulation of the enteric environment. J Gastroenterol. 2003;38:134–141.
   PubMed Web of Science ®Google Scholar
• Araki Y, Kanauchi O, Sugihara H, et al. Germinated barley foodstuff suppresses dextran sulphate experimental colitis in rats: the role of mast cells. Int J Mol Med. 2007;19:257–262.
   PubMed Web of Science ®Google Scholar
• Araki Y, Fujiyama Y, Andoh A, et al. The dietary combination of germinated barley foodstuff plus Clostridium butyricum suppresses the dextran sulphate sodium-induced experimental colitis in rats. Scand J Gastroenterol. 2000;35:1060–1067.
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Oshima T, Andoh A, et al. Germinated barley foodstuff ameliorates inflammation in mice with colitis through modulation of mucosal immune system. Scand J Gastroenterol. 2008;43:1346–1352.
   PubMed Web of Science ®Google Scholar
• Mitsuyama K, Saiki T, Kanauchi O, et al. Treatment of ulcerative colitis with germinated barley foodstuff feeding: a pilot study. Aliment Pharmacol Ther. 1998;12:1225–1230.
   PubMed Web of Science ®Google Scholar
• Kanauchi O, Suga T, Tochihara M, et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicentre open control trial. J Gastroenterol. 2002;37(Suppl XIV): 67–72.
   Web of Science ®Google Scholar
• Kanauchi O, Mitsuyama K, Homma T, et al. Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int J Mol Med. 2003;12:701–704.
   PubMed Web of Science ®Google Scholar
• Faghfoori Z, Shakerhosseini R, Navai L, et al. Effects of an oral supplementation of germinated barley foodstuff on serum CRP level and clinical signs in patients with ulcerative colitis. Health Promot Perspect. 2014;4:116–121.
   PubMedGoogle Scholar
• Faghfoori Z, Navai L, Shakerhosseini R, et al. Effects of an oral supplementation of germinated barley foodstuff on serum tumor necrosis factor-α, interleukin-6 and -8 in patients with ulcerative colitis. Ann Clin Biochem. 2011;48:233–237.
   PubMed Web of Science ®Google Scholar
• Hanai H, Kanauchi O, Mitsuyama K, et al. Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. Int J Mol Med. 2004;13:643–647.
   PubMed Web of Science ®Google Scholar
• Vénica CI, Bergamini CV, Rebechi SR, et al. Galacto-oligosaccharides formation during manufacture of different varieties of yogurt. Stability through storage. LWT-Food Sci Technol. 2015;63:198–205.
   Web of Science ®Google Scholar
• Holma R, Juvonen P, Asmawi MZ, et al. Galacto-oligosaccharides stimulate the growth of bifidobacteria but fail to attenuate inflammation in experimental colitis in rats. Scand J Gastroenterol. 2002;37:1042–1047.
   PubMed Web of Science ®Google Scholar
• Davis LMG, Martínez I, Walter J, et al. A dose dependent impact of prebiotic galactooligosaccharides on the intestinal microbiota of healthy adults. Int J Food Microbiol. 2010;144:285–292.
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Matsumoto S, Ohashi Y, et al. Beneficial effects of probiotic Bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomised controlled study. Digestion. 2011;84:128–133.
   PubMed Web of Science ®Google Scholar
• Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20:1133–1141.
   PubMed Web of Science ®Google Scholar
• Chen X, Zuo Q, Hai Y, et al. Lactulose: an indirect antioxidant ameliorating inflammatory bowel disease by increasing hydrogen production. Med Hypotheses. 2011;76:325–327.
   PubMed Web of Science ®Google Scholar
• Mao B, Li D, Zhao J, et al. In vitro fermentation of lactulose by human gut bacteria. J Agric Food Chem. 2014;62:10970–10977.
   PubMed Web of Science ®Google Scholar
• Vanhoutte T, De Preter V, De Brandt E, et al. Molecular monitoring of the faecal microbiota of healthy human subjects during the administration of lactulose and Saccharomyces boulardii. Appl Environ Microbiol. 2006;72:5990–5997.
   PubMed Web of Science ®Google Scholar
• Rumi G, Tsubouchi R, Okayama M, et al. Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats . Dig Dis Sci. 2004;49:1466–1472.
   PubMed Web of Science ®Google Scholar
• Hafer A, Krämer S, Duncker S, et al. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 2007;7:36.
   PubMed Web of Science ®Google Scholar
• Diaz-Gerevini GT, Repossi G, Dain A, et al. Beneficial action of resveratrol: how and why? Nutrition. 2016;32:174–178.
   PubMed Web of Science ®Google Scholar
• Bode LM, Bunzel D, Huch M, et al. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr. 2013;97:295–309.
   PubMed Web of Science ®Google Scholar
• Samsamikor M, Daryani NE, Asl PR, et al. Anti-inflammatory effects of resveratrol in patients with ulcerative colitis: a randomized, double-blind, placebo-controlled pilot study. Arch Med Res. 2015;46:280–285.
   PubMed Web of Science ®Google Scholar
• Sánchez-Fidalgo S, Cárdeno A, Villegas I, et al. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol. 2010;633:78–84.
   PubMed Web of Science ®Google Scholar
• Larossa M, Yañéz-Gascón MJ, Selma MV, et al. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem. 2009;57:2211–2220.
   PubMed Web of Science ®Google Scholar
• Etxeberria U, Arias N, Boqué N, et al. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose fed rats. J Nutr Biochem. 2015;26:652–660.
   Web of Science ®Google Scholar
• Ghouri Y, Richards DM, Rahimi EF, et al. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014;7:473–487.
   PubMedGoogle Scholar
• Derikx LAAP, Dielemann LA, Hoentjen F. Probiotics and prebiotics in ulcerative colitis. Best Pract Res Clin Gastroenterol. 2016;30:55–71.
   PubMed Web of Science ®Google Scholar
• Macfarlane GT, Macfarlane S. Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int. 2012;95:50–60.
   PubMed Web of Science ®Google Scholar
• Rajilić-Stojanović M, Shanahan F, Guarner F, et al. Phylogenetic analysis of dysbiosis in ulcerative colitis during remission. Inflamm Bowel Dis. 2013;19:481–488.
   PubMed Web of Science ®Google Scholar
• Png CW, Lindén SK, Gilshenan KS, et al. Mycolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010;105:2420–2428.
   PubMed Web of Science ®Google Scholar
• Fischer H, Holst E, Karlsson F, et al. Altered microbiota in microscopic colitis. Gut 2015;64:1185–1186.
   PubMed Web of Science ®Google Scholar
• Morse A, Dlusskaya EA, Valcheva R, et al. T2041 Prebiotic mixture of inulin plus oligofructose is effective adjunct therapy for treatment of mild to moderate ulcerative colitis. Gastroenterology. 2010;138(Suppl. 1):S-619.
   Web of Science ®Google Scholar
• Guslandi M. Efficacy of a symbiotic product during clinical relapse of ulcerative colitis. J Clin Gastroenterol. 2011;45:475–476.
   PubMed Web of Science ®Google Scholar
• Haskey N, Dahl WJ. Synbiotic therapy improves quality of life and reduces symptoms in paediatric ulcerative colitis. Infant Child Adolesc Nutr. 2009;1:88–93.
   Google Scholar
• Kanauchi O, Mitsuyama K, Andoh A, et al. Beneficial effects of prebiotics, germinated barley foodstuff, in the long term treatment of ulcerative colitis: a multi-center open control study. Gastroenterology. 2003;124(Suppl. 1):A260.
   Web of Science ®Google Scholar